$AIP

RAZA SAIYED ATIQ sold $435K of AIP (indirect holdings)

RAZA SAIYED ATIQ sold 11,707 indirectly-held shares of Arteris, Inc. (AIP) at $37.13 ($0.43M total) on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAZA SAIYED ATIQ
Published Jun 4, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AIP
Neutral
medium confidence
Mentioned
$AIP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The disclosure confirms an open-market sale by a director at a stated price and share count, but the presence of a pre-arranged 10b5-1 plan reduces the likelihood of it signaling new negative information.

02

Market read

Traders may monitor AIP for any follow-on insider activity, but this filing alone is unlikely to reset valuation or expectations.

03

What to watch

Consider whether there were multiple recent insider transactions or changes in total insider ownership; a single sale may be statistically noisy.

Relevance 6/10Novelty 5/10Timing: Filed today; sale occurred on 2026-06-03 (disclosed 2026-06-04).

Background

This is a SEC Form 4 insider transaction disclosure for Arteris, Inc. (AIP), submitted via EDGAR.

Company-level read

Ticker impact

$AIPNeutralMedium confidence
Context

Arteris director RAZA SAIYED ATIQ sold 11,707 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low-to-moderate near-term downside bias possible, but unlikely to drive a sustained move absent other catalysts.

Evidence & confidence

The filing provides a concrete sale size and price ($37.1294) but explicitly indicates a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No direct sector read-through; this is company-specific insider disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than negative expectations—market may overreact.

Key entities

  • Arteris, Inc.

    Subject of the Form 4 insider sale disclosure.

  • RAZA SAIYED ATIQ

    Director who sold 11,707 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AIPMedAI 8/10

Arteris (AIP) Q2 2026 Earnings Call Transcript

Arteris, Inc. (AIP) reported Q2 2026 revenue of $24.1 million, up 46% year over year. ACV plus royalties were $99.5 million, up 44%, and remaining performance obligation was $135 million, up 36%. Cash and investments rose to $123 million after an at-the-market raise. Full-year 2026 revenue guidance was raised to $95-$98 million.

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, to